The Role of Immune Semaphorins in Steatotic Liver Disease and Sepsis

Last updated: September 1, 2023
Sponsor: University Hospital for Infectious Diseases, Croatia
Overall Status: Active - Recruiting

Phase

N/A

Condition

Allergy

Primary Biliary Cholangitis

Soft Tissue Infections

Treatment

Evaluation of the degree of steatosis

Measurement of serum semaphorin concentrations

Screening for the components of metabolic syndrome

Clinical Study ID

NCT06021743
UHID-08
  • Ages > 18
  • All Genders

Study Summary

The impact of the complex liver immunological network on sepsis outcome is largely unknown. Steatotic liver disease (SLD) is the most common chronic liver disease with prevalence of 25% in European countries. The question remains whether patients with SLD are more prone to bacterial infections and what is the impact of persistent liver inflammation to the systemic response to infection, sepsis course and outcomes. Semaphorins are a large family of secreted and membrane-bound biological response modifiers present in many organ systems that are associated with SLD and development of fibrosis, but also might regulate systemic immune responses in sepsis. This study will investigate the association of semaphorins with sepsis outcomes in patients with SLD.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 2 or more SIRS (Systemic Inflammatory Response Syndrome) criteria (1. Hyperthermia >38.3°C or Hypothermia <36°C; 2. Tachycardia >90 bpm; 3. Tachypnea >20 bpm; 3.Leukocytosis (>12,000 μL-1) or Leukopenia (<4,000 μL-1))
  • clinical suspicion of sepsis
  • enrolled within 24 hours of hospital admission

Exclusion

Exclusion Criteria:

  • no consent
  • immunosuppression
  • malignancies
  • immune diseases
  • pregnancy
  • HIV infection
  • presence of chronic liver disease
  • consumption of alcohol > 20 g/day

Study Design

Total Participants: 160
Treatment Group(s): 4
Primary Treatment: Evaluation of the degree of steatosis
Phase:
Study Start date:
January 01, 2022
Estimated Completion Date:
March 01, 2024

Study Description

The liver, with its ability to produce acute phase proteins, complement and cytokines, plays a central role in regulating inflammation. A balanced pro- and anti-inflammatory liver response results in bacterial clearance and resolution of inflammation. Steatotic liver disease (SLD) is the most common chronic liver disease associated with systemic changes in immune response. Although there are numerous immunological links between sepsis and SLD, there is a significant gap in knowledge regarding the role of SLD in sepsis. Semaphorins were recently recognized as one of the key regulators of immune responses; while some suppress immune cells activation, proliferation and production of inflammatory cytokines, others stimulate immune responses. Semaphorins were recently shown to be associated with pathogenesis of viral hepatitis, SLD and progression of fibrosis. However, their role in sepsis is unknown. The hypothesis of this project is that semaphorins are regulators of inflammation in patients with SLD that have impact on sepsis outcome.

Connect with a study center

  • University Hospital for Infectious Diseases Zagreb

    Zagreb, 10000
    Croatia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.